Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRWD NASDAQ:OLMA NASDAQ:TVTX NASDAQ:ZEAL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRWDIronwood Pharmaceuticals$1.55-3.7%$1.30$0.53▼$5.13$261.52M0.31.31 million shs1.21 million shsOLMAOlema Pharmaceuticals$9.60-7.4%$7.78$2.86▼$13.51$711.74M2.081.21 million shs2.00 million shsTVTXTravere Therapeutics$27.51+2.5%$22.01$12.91▼$28.69$2.39B0.831.88 million shs2.30 million shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRWDIronwood Pharmaceuticals-3.73%-12.43%+19.23%+101.95%-65.56%OLMAOlema Pharmaceuticals-7.43%-10.11%+21.67%+117.69%-21.95%TVTXTravere Therapeutics+2.46%+5.52%+20.82%+70.76%+52.41%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRWDIronwood Pharmaceuticals$1.55-3.7%$1.30$0.53▼$5.13$261.52M0.31.31 million shs1.21 million shsOLMAOlema Pharmaceuticals$9.60-7.4%$7.78$2.86▼$13.51$711.74M2.081.21 million shs2.00 million shsTVTXTravere Therapeutics$27.51+2.5%$22.01$12.91▼$28.69$2.39B0.831.88 million shs2.30 million shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRWDIronwood Pharmaceuticals-3.73%-12.43%+19.23%+101.95%-65.56%OLMAOlema Pharmaceuticals-7.43%-10.11%+21.67%+117.69%-21.95%TVTXTravere Therapeutics+2.46%+5.52%+20.82%+70.76%+52.41%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRWDIronwood Pharmaceuticals 2.25Hold$4.94218.71% UpsideOLMAOlema Pharmaceuticals 2.63Moderate Buy$23.33143.06% UpsideTVTXTravere Therapeutics 2.81Moderate Buy$35.2128.01% UpsideZEALZealand Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TVTX, OLMA, ZEAL, and IRWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025TVTXTravere TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025OLMAOlema PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OLMAOlema PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.0010/8/2025TVTXTravere TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/6/2025IRWDIronwood PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025OLMAOlema PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TVTXTravere TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/12/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$20.00 ➝ $25.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRWDIronwood Pharmaceuticals$351.41M0.72$0.05 per share32.55($1.88) per share-0.82OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ATVTXTravere Therapeutics$233.18M10.52N/AN/A$0.76 per share36.20ZEALZealand Pharma A/S$46.54M17.59N/AN/A$3.38 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRWDIronwood Pharmaceuticals$880K-$0.05N/A6.20N/A-2.25%-2.46%2.19%11/6/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)ZEALZealand Pharma A/S-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/ALatest TVTX, OLMA, ZEAL, and IRWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025OLMAOlema Pharmaceuticals-$0.44N/AN/AN/AN/AN/A11/6/2025Q3 2025IRWDIronwood Pharmaceuticals$0.08N/AN/AN/A$74.22 millionN/A10/30/2025Q3 2025TVTXTravere Therapeutics-$0.31N/AN/AN/AN/AN/A8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/7/2025Q2 2025IRWDIronwood Pharmaceuticals-$0.02$0.14+$0.16$0.14$62.02 million$85.24 million8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRWDIronwood PharmaceuticalsN/A0.820.82OLMAOlema Pharmaceuticals0.0111.0911.09TVTXTravere Therapeutics9.502.001.98ZEALZealand Pharma A/S0.934.794.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRWDIronwood PharmaceuticalsN/AOLMAOlema Pharmaceuticals91.78%TVTXTravere TherapeuticsN/AZEALZealand Pharma A/S1.73%Insider OwnershipCompanyInsider OwnershipIRWDIronwood Pharmaceuticals12.70%OLMAOlema Pharmaceuticals16.36%TVTXTravere Therapeutics4.19%ZEALZealand Pharma A/S2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRWDIronwood Pharmaceuticals220162.43 million141.81 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableTVTXTravere Therapeutics46089.14 million85.40 millionOptionableZEALZealand Pharma A/S35546.54 million45.51 millionNot OptionableTVTX, OLMA, ZEAL, and IRWD HeadlinesRecent News About These CompaniesNew Zealand's pharma growth complements ongoing FTA negotiations with India to boost pharma tradeOctober 10, 2025 | pharmabiz.comPBig pharma firms announce direct-to-consumer sales and price cuts in U.S.October 2, 2025 | reuters.comThe Top Big Pharmas Have $1.2T in Stretch M&A Firepower AvailableOctober 1, 2025 | biospace.comBFactbox-Big pharma firms announce direct-to-consumer sales and price cuts in U.S.October 1, 2025 | msn.comPharma Stocks Vary Worldwide Following New Trump TariffsSeptember 26, 2025 | finance.yahoo.comZealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media RelationsSeptember 24, 2025 | globenewswire.comEuropean stocks end higher with monetary policy in focus; Zealand Pharma gains 8%September 19, 2025 | msn.comZealand Pharma increases its share capital as a result of the exercise of employee warrantsSeptember 11, 2025 | globenewswire.comSAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025September 11, 2025 | globenewswire.comZealand Pharma to participate in upcoming investor conferences in September 2025August 28, 2025 | globenewswire.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.August 20, 2025 | globenewswire.comQ2 2025 Zealand Pharma A/S Earnings Call TranscriptAugust 14, 2025 | gurufocus.comZealand Pharma Announces Financial Results for the First Half of 2025August 14, 2025 | globenewswire.comZealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial resultsAugust 7, 2025 | globenewswire.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.July 18, 2025 | markets.businessinsider.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.July 18, 2025 | globenewswire.comZealand Pharma A/S. (ZLDPF) Institutional Holdings | NasdaqJuly 11, 2025 | nasdaq.comZealand Pharma A/S. (ZLDPF) Analyst Research | NasdaqJuly 11, 2025 | nasdaq.comStock Movers: Sainsbury's, Zealand Pharma, Taylor WimpeyJuly 1, 2025 | bloomberg.comZealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for MoreJune 20, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVTX, OLMA, ZEAL, and IRWD Company DescriptionsIronwood Pharmaceuticals NASDAQ:IRWD$1.55 -0.06 (-3.73%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$1.55 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$9.60 -0.77 (-7.43%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$9.55 -0.05 (-0.52%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Travere Therapeutics NASDAQ:TVTX$27.51 +0.66 (+2.46%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$26.32 -1.19 (-4.31%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Zealand Pharma A/S NASDAQ:ZEALZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
